CD36 repression activates a multicellular stromal program shared by high mammographic density and tumor tissues

Cancer Discovery

Volumn 2, Issue 9, 2012, Pages 826-839

  DeFilippis, Rosa Anna ^a,b   Chang, Hang ^d   Dumont, Nancy ^a,b   Rabban, Joseph T ^a   Chen, Yunn Yi ^a   Fontenay, Gerald V ^d   Berman, Hal K ^e   Gauthier, Mona L ^e   Zhao, Jianxin ^a,b   Hu, Donglei ^a   Marx, James J ^f   Tjoe, Judy A ^f   Ziv, Elad ^a   Febbraio, Maria ^g   Kerlikowske, Karla ^a,c   Parvin, Bahram ^d   Tlsty, Thea D ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f AURORA HEALTH CARE   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD36 ANTIGEN; COLLAGEN TYPE 1; FIBRONECTIN; OSTEOPONTIN;

ADIPOCYTE; ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FIBROBLAST; GENE REPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LIPID STORAGE; MAMMOGRAPHY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; STROMA CELL;

ADIPOCYTES; ANIMALS; ANTIGENS, CD36; BREAST NEOPLASMS; CELL DIFFERENTIATION; FEMALE; HUMANS; MAMMOGRAPHY; MICE; MICE, KNOCKOUT; RISK FACTORS; SIGNAL TRANSDUCTION; STROMAL CELLS;

EID: 84866312491     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-12-0107     Document Type: Article

References (50)

1. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2006; 6: 392-401.
2. Arendt LM, Rudnick JA, Keller PJ, Kuperwasser C. Stroma in breast development and disease. Semin Cell Dev Biol 2010; 21: 11-8.
3. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008; 14: 518-27.
4. Tlsty TD, Coussens LM. Tumor stroma and regulation of cancer development. Annu Rev Pathol 2006; 1: 119-50.
5. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999; 59: 5002-11.
6. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121: 335-48.
7. Walker RA. The complexities of breast cancer desmoplasia. Breast Cancer Res 2001; 3: 143-45.
8. Bing C, Trayhurn P. New insights into adipose tissue atrophy in cancer cachexia. Proc Nutr Soc 2009; 68: 385-92.
9. Guo YP, Martin LJ, Hanna W, Banerjee D, Miller N, Fishell E, et al. Growth factors and stromal matrix proteins associated with mammographic densities. Cancer Epidemiol Biomarkers Prev 2001; 10: 243-48.
10. Li T, Sun L, Miller N, Nicklee T, Woo J, Hulse-Smith L, et al. The association of measured breast tissue characteristics with mammographic density and other risk factors for breast cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 343-9.
11. Byrne C, Schairer C, Wolfe J, Parekh N, Salane M, Brinton L A, et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 1995; 87: 1622-9.
12. Kerlikowske K, Shepherd J, Creasman J, Tice JA, Ziv E, Cummings SR. Are breast density and bone mineral density independent risk factors for breast cancer? J Natl Cancer Inst 2005; 97: 368-74.
13. Boyd NF, Byng JW, Jong RA, Fishell EK, Little LE, Miller AB, et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 1995; 87: 670-5.
14. Cummings SR, Tice JA, Bauer S, Browner WS, Cuzick J, Ziv E, et al. Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst 2009; 101: 384-98.
15. Ziv E, Tice J, Smith-Bindman R, Shepherd J, Cummings S, Kerlikowske K. Mammographic density and estrogen receptor status of breast cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 2090-5.
16. Boyd NF, Dite GS, Stone J, Gunasekara A, English DR, McCredie MR, et al. Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med 2002; 347: 886-94.
17. Ursin G, Lillie EO, Lee E, Cockburn M, Schork NJ, Cozen W, et al. The relative importance of genetics and environment on mammographic density. Cancer Epidemiol Biomarkers Prev 2009; 18: 102-12.
18. Chlebowski RT, McTiernan A. Biological significance of interventions that change breast density. J Natl Cancer Inst 2003; 95: 4-5.
19. Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, et al. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst 2011; 103: 744-52.
20. El-Bastawissi AY, White E, Mandelson MT, Taplin SH. Reproductive and hormonal factors associated with mammographic breast density by age (United States). Cancer Causes Control 2000; 11: 955-63.
21. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003; 95: 30-7.
22. Haakensen VD, Biong M, Lingjaerde OC, Holmen MM, Frantzen JO, Chen Y, et al. Expression levels of uridine 5C-diphospho-glucuronosyltransferase genes in breast tissue from healthy women are associated with mammographic density. Breast Cancer Res 2010; 12: R65.
23. Yang WT, Lewis MT, Hess K, Wong H, Tsimelzon A, Karadag N, et al. Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat 2010; 119: 305-14.
24. Vachon CM, Sasano H, Ghosh K, Brandt KR, Watson DA, Reynolds C, et al. Aromatase immunoreactivity is increased in mammographically dense regions of the breast. Breast Cancer Res Treat 2011; 125: 243-52.
25. Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal 2009; 2: re3.
26. Chang H, DeFilippis RA, Tlsty TD, Parvin B. Graphical methods for quantifying macromolecules through bright field imaging. Bioinformatics 2009; 25: 1070-5.
27. Gregoire FM, Smas CM, Sul HS. Understanding adipocyte differentiation. Physiol Rev 1998; 78: 783-809.
28. Sfeir Z, Ibrahimi A, Amri E, Grimaldi P, Abumrad N. CD36 antisense expression in 3T3-F442A preadipocytes. Mol Cell Biochem 1999; 192: 3-8.
29. Febbraio M, Abumrad NA, Hajjar DP, Sharma K, Cheng W, Pearce SF, et al. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem 1999; 274: 19055-62.
30. Yaghjyan L, Colditz GA, Collins LC, Schnitt SJ, Rosner B, Vachon C, et al. Mammographic breast density and subsequent risk of breast cancer in postmenopausal women according to tumor characteristics. J Natl Cancer Inst 2011; 103: 1179-89.
31. Pereira SM, McCormack VA, Hipwell JH, Record C, Wilkinson LS, Moss SM, et al. Localized fibroglandular tissue as a predictor of future tumor location within the breast. Cancer Epidemiol Biomarkers Prev 2011; 20: 1718-25.
32. Aiello EJ, Buist DS, White E, Porter PL. Association between mammographic breast density and breast cancer tumor characteristics. Cancer Epidemiol Biomarkers Prev 2005; 14: 662-8.
33. Kerlikowske K, Cook AJ, Buist DS, Cummings SR, Vachon C, Vacek P, et al. Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use. J Clin Oncol 2010; 28: 3830-7.
34. Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, et al. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 2008; 9: 239.
35. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007; 25: 1239-46.
36. Primo L, Ferrandi C, Roca C, Marchio S, di Blasio L, Alessio M, et al. Identification of CD36 molecular features required for its in vitro angiostatic activity. FASEB J 2005; 19: 1713-5.
37. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000; 6: 41-8.
38. Kennedy DJ, Kuchibhotla S, Westfall KM, Silverstein RL, Morton RE, Febbraio M. A CD36-dependent pathway enhances macrophage and adipose tissue inflammation and impairs insulin signalling. Cardiovasc Res 2011; 89: 604-13.
39. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, et al. Macrophage polarization in tumour progression. Semin Cancer Biol 2008; 18: 349-55.
40. McDonnell AM, Robinson BW, Currie AJ. Tumor antigen crosspresentation and the dendritic cell: where it all begins? Clin Dev Immunol 2010; 2010: 539519.
41. Landskroner-Eiger S, Qian B, Muise ES, Nawrocki AR, Berger JP, Fine EJ, et al. Proangiogenic contribution of adiponectin toward mammary tumor growth in vivo. Clin Cancer Res 2009; 15: 3265-76.
42. Provenzano PP, Inman DR, Eliceiri KW, Knittel JG, Yan L, Rueden CT, et al. Collagen density promotes mammary tumor initiation and progression. BMC Med 2008; 6: 11.
43. Engler AJ, Sen S, Sweeney HL, Discher DE. Matrix elasticity directs stem cell lineage specification. Cell 2006; 126: 677-89.
44. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009; 139: 891-906.
45. Vinals M, Bermudez I, Llaverias G, Alegret M, Sanchez RM, Vazquez-Carrera M, et al. Aspirin increases CD36, SR-BI, and ABCA1 expression in human THP-1 macrophages. Cardiovasc Res 2005; 66: 141-9.
46. Matasic R, Dietz AB, Vuk-Pavlovic S. Dexamethasone inhibits dendritic cell maturation by redirecting differentiation of a subset of cells. J Leukoc Biol 1999; 66: 909-14.
47. Ruiz-Velasco N, Dominguez A, Vega MA. Statins upregulate CD36 expression in human monocytes, an effect strengthened when combined with PPAR-gamma ligands Putative contribution of Rho GTPases in statin-induced CD36 expression. Biochem Pharmacol 2004; 67: 303-13.
48. Boyer JF, Balard P, Authier H, Faucon B, Bernad J, Mazieres B, et al. Tumor necrosis factor alpha and adalimumab differentially regulate CD36 expression in human monocytes. Arthritis Res Ther 2007; 9: R22.
49. Saibara T, Ogawa Y, Onishi S. Tamoxifen in early breast cancer. Lancet 1998; 352: 404.
50. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-64.